VCE-003

a cannabigerol quinone; structure in first source

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

1.	Cantarero, Irene: 2 articles (01/2014 - 12/2012)
2.	Guaza, Carmen: 2 articles (01/2014 - 12/2012)
3.	Mecha, Miriam: 2 articles (01/2014 - 12/2012)
4.	Muñoz, Eduardo: 2 articles (01/2014 - 12/2012)
5.	Navarrete, Carmen: 2 articles (01/2014 - 12/2012)
6.	Bellido, María L: 1 article (01/2014)
7.	Carrillo-Salinas, Francisco J: 1 article (01/2014)
8.	Collado, Juan A: 1 article (01/2014)
9.	Feliú, Ana: 1 article (01/2014)
10.	Appendino, Giovanni: 1 article (12/2012)

1.	Immune System Diseases (Immune Disorders) 01/01/2014 - "This study highlights the therapeutic potential of VCE-003 as an agent for the treatment of human immune diseases with both inflammatory and autoimmune components."
2.	Multiple Sclerosis 01/01/2014 - "A cannabigerol quinone, the compound VCE-003, has been shown to alleviate symptoms in a viral model of multiple sclerosis (MS). "
3.	Infections 12/01/2012 - "We found that VCE-003 ameliorated the symptoms associated to TMEV infection, decreased microglia reactivity and modulated the expression of genes involved in MS pathophysiology. "
4.	Neuroinflammatory Diseases 12/01/2012 - "These data lead us to consider VCE-003 to have high potential for drug development against MS and perhaps other neuroinflammatory diseases."